Nanjing/P.R. China and Singapore, December 15th, 2014 InvitroCueand Nanjing KCI Biotech have signed an agreement to establish a strategic partnership with the aim to provide image analysis services for preclinical drug testing. KCI is a preclinical contract research organization (CRO) with core competency in developing and running specialized animal disease models for drug testing and medical device testing. KCI has chosen InvitroCue, a specialist in digital pathology, as its exclusive service partner for image-based analysis. In addition, both companies will collaborate to develop new tools and validateInvitroCue’s existing image processing applications. “We are pleased to have entered this agreement with Nanjing KCI Biotech. It allows us to leverage on KCI’s expertise in preclinical research and specialized animal disease models. It also helps InvitroCue to extend its presence in China and to promote digital pathology”, said Dr Steven Fang, Founder and CEO of InvitroCue. “The partner...